ArticleFrontiers in oncology2026
Frailty phenotype and long-term mortality after curative colorectal cancer surgery: a retrospective multicenter cohort study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Frailty is associated with poor short-term surgical outcomes, but whether the Fried frailty phenotype is associated with long-term mortality after curative colorectal cancer (CRC) surgery, independently of age and tumor stage, is uncertain. We examined this association using restricted mean survival time (RMST), which does not require proportional hazards. Methods: This retrospective multicenter cohort study included 304 patients aged ≥60 years who underwent curative CRC surgery at three centers in China in 2018-2019. The preoperative Fried phenotype was analyzed as robust (n=131), pre-frail (n=57), or frail (n=116); binary (robust versus non-robust) and ordinal codings were secondary. The primary outcome was 5-year all-cause mortality. Because proportional hazards were violated (Schoenfeld test P = 0.011), the RMST difference at 60 months was the primary effect measure, adjusted by pseudo-observation regression for age, sex, and TNM stage, the minimal adjustment set from a directed acyclic graph. Stage-specific and time-varying-effect analyses were also performed. Results: Over a median follow-up of 60 months, 27 patients (8.9%) died. Five-year survival was 96.2%, 84.2%, and 88.8% in robust, pre-frail, and frail patients (log-rank P = 0.015). Unadjusted RMST differences versus robust patients were -2.38 months (95% CI -4.45 to -0.78) for pre-frail and -2.73 months (-4.58 to -1.09) for frail patients. After adjustment for age, sex, and TNM stage they were -1.48 months (-3.42 to 0.45; P = 0.13) and -0.81 months (-2.56 to 0.93; P = 0.36); for non-robust versus robust patients, -1.16 months (-2.50 to 0.19; P = 0.092). Estimates were in the same direction within every stage but imprecise. The hazard ratio for non-robust patients appeared higher in the first 36 months than later, but period-specific estimates were unstable and did not differ significantly (P = 0.15). Conclusions: The Fried frailty phenotype identified older patients with lower 5-year survival after curative CRC surgery. After adjustment for age and tumor stage the association was attenuated and imprecise, so an independent effect could not be established with 27 deaths. The apparent early concentration of excess mortality in non-robust patients is hypothesis-generating and requires confirmation in larger cohorts with treatment and cause-of-death data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.